Active ingredient: Dacarbazine - Basic Profile / Key Facts

Basic Profile / Key Facts

Drug Category

• Antineoplastic Agents

Dosage Forms

• Liquid
• Powder for solution

Indications

For the treatment of metastatic malignant melanoma. In addition, DTIC-Dome is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents

Pharmacology

After intravenous administration of DTIC-Dome, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged DTIC in the urine is 40% of the injected dose in 6 hours. 1 DTIC is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations DTIC is not appreciably bound to human plasma protein.

Mechanism of Action

Possibly blocking the formation of inosinic acid.

Absorption

Erratic, slow and incomplete

Toxicity

LD₅₀=350mg/kg (orally in mice)

Biotrnasformation / Drug Metabolism

Hepatic

Contraindications

DTIC-Dome is contraindicated in patients who have demonstrated a hypersensitivity to it in the past.

Drug Interactions

No Information Provided.